Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why.

Core Viewpoint - Trump's proposal of a 100% tariff on imported branded or patented drugs has created a dramatic scenario, yet pharmaceutical stocks have generally performed well, indicating resilience in the sector as companies announce investments in the U.S. [1] Group 1 - The threat of a 100% tariff on imported drugs is significant but has not negatively impacted pharma stock performance [1] - Recent months have seen a surge in announcements from pharmaceutical companies regarding plans to invest in the U.S. [1]